Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
55
TNXP Quote, Financials, Valuation and Earnings
Last price:
$47.00
Seasonality move
:
-16.6%
Day range:
$43.80 - $46.90
52-week range:
$6.76 - $130.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.31x
P/B ratio:
1.83x
Volume:
1.3M
Avg. volume:
774.1K
1-year change:
-26.23%
Market cap:
$330.1M
Revenue:
$10.1M
EPS (TTM):
-$1,963.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$2.6M | -$1.88 | 17.75% | -99.9% | $61.67 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.35 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$45.06 | $61.67 | $330.1M | -- | $0.00 | 0% | 12.31x |
|
ATNM
Actinium Pharmaceuticals
|
$1.59 | $5.00 | $49.6M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.60 | -- | $25.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.42 | $1.00 | $1M | -- | $0.00 | 0% | 0.45x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
-- | -1.879 | -- | 11.24x |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.037 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$1.5M | -$15.1M | -114.25% | -121.16% | -622.93% | -$16.6M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Tonix Pharmaceuticals Holding vs. Competitors
-
Which has Higher Returns TNXP or ATNM?
Actinium Pharmaceuticals has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of -11511.11%. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About TNXP or ATNM?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 36.86%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 214.47%. Given that Actinium Pharmaceuticals has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Actinium Pharmaceuticals is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is TNXP or ATNM More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.
-
Which is a Better Dividend Stock TNXP or ATNM?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or ATNM?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 12.31x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding12.31x -- $2.4M -$16.8M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns TNXP or NBY?
NovaBay Pharmaceuticals has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of -49.65%. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About TNXP or NBY?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 36.86%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Tonix Pharmaceuticals Holding has higher upside potential than NovaBay Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is TNXP or NBY More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock TNXP or NBY?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or NBY?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 12.31x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding12.31x -- $2.4M -$16.8M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns TNXP or NNVC?
Nanoviricides has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About TNXP or NNVC?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 36.86%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Nanoviricides has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Nanoviricides is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 NNVCNanoviricides0 0 0 -
Is TNXP or NNVC More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock TNXP or NNVC?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or NNVC?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Nanoviricides quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Nanoviricides's net income of -$2.2M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 12.31x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding12.31x -- $2.4M -$16.8M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns TNXP or OGEN?
Oragenics has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M OGENOragenics-- -$3.60 -- -
What do Analysts Say About TNXP or OGEN?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 36.86%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Oragenics is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 OGENOragenics0 1 0 -
Is TNXP or OGEN More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock TNXP or OGEN?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or OGEN?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Oragenics's net income of -$2.2M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 12.31x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding12.31x -- $2.4M -$16.8M OGENOragenics0.45x -- -- -$2.2M
-
Which has Higher Returns TNXP or TOVX?
Theriva Biologics has a net margin of -692.84% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -121.16% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding61.18% -$2.84 $180.4M TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About TNXP or TOVX?
Tonix Pharmaceuticals Holding has a consensus price target of $61.67, signalling upside risk potential of 36.86%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Theriva Biologics is more attractive than Tonix Pharmaceuticals Holding.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 TOVXTheriva Biologics1 1 0 -
Is TNXP or TOVX More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.054, which suggesting that the stock is 105.447% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock TNXP or TOVX?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or TOVX?
Tonix Pharmaceuticals Holding quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$16.8M is lower than Theriva Biologics's net income of -$4.3M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 12.31x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding12.31x -- $2.4M -$16.8M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 5.43% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is up 0.79% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 210.05% over the past day.
